Nakamuraya Co., Ltd. operates in the Candy & other confectionery products sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Nakamuraya Co., Ltd. with three other
bakery and confectionary companies in Asia:
GlaxoSmithKline Consumer Healthcare Limited
sales of 43.17 billion Indian Rupees [US$626.76 million]
of which 100%
Sampre Nutritions Ltd
(326.47 million Indian Rupees [US$4.74 million]
Imuraya Group Company Limited
(45.06 billion Japanese Yen [US$406.46 million]
of which 88%
was Distribution Business).
Nakamuraya Co., Ltd. reported sales of ¥41.36 billion (US$373.05 million)
March of 2018.
decrease of 1.3%
versus 2017, when the company's sales were ¥41.90 billion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Nakamuraya Co., Ltd. had sales
of ¥40.38 billion.
Contributing to the drop in overall sales was the 50.1% decline
in Real Estate Leasing Business, from ¥1.16 billion to ¥578.36 million.
However, these declines were partially offset by the increase in sales of
Confectionery Business (up 2.9% to ¥30.52 billion)
Food Business (up 28.5% to ¥9.27 billion)
Other Businesses (up 6.5% to ¥992.20 million)